J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
JNJ's regulatory filing seeks the FDA's approval for TAR-200, a drug-device combination for treating certain bladder cancer ...
The 6 signs of ‘hard to spot’ bile duct cancer that kills majority of patients within a year
FOR the 6,000 people in the UK who are newly diagnosed with bile duct cancer every year, the prognosis is uniquely grim.
pharmaphorum2d
J&J files intravesical bladder cancer drug TAR-200 in US
J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...
Keighley deli owner Paul Simmonite trialling new cancer drug
A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.
Keighley News2d
Keighley deli owner in trials of new cancer drug
A KEIGHLEY deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.
Targeted Oncology3d
FDA Considers TAR-200 in BCG-Unresponsive High-Risk NMIBC
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
Cure Today5d
Sasanlimab Improves Event-Free Survival for Some With Bladder Cancer
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Targeted Oncology5d
Sasanlimab Plus BCG Demonstrates EFS Benefit in NMIBC
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
What are the symptoms of bladder cancer – and how is it treated?
A specialist can diagnose bladder cancer using a variety of tests. “Bladder cancer can be diagnosed through a combination of ...
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...